搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
Pharmaceutical Technology
10 天
Opzelura by Incyte for Unspecified Dermatological Disorders: Likelihood of Approval
Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.
Pharmaceutical Technology
17 天
Opzelura by Incyte for Vulvar Lichen Sclerosus: Likelihood of Approval
Ruxolitinib phosphate (INCB-018424) is under development for the treatment of prurigo nodularis (PN), graft versus host disease, discoid lupus erythematosus, vitiligo and atopic dermatitis, hand ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Los Angeles wildfire updates
California fires: How to help
Israel, Hamas ceasefire deal
Bans use of Red No. 3 dye
Plans tax hikes on rich
New definition of obesity
Announces run for governor
‘Cheers’ actor dies at 79
Trans sports bill passed
Designates 2 monuments
FBI erases Chinese malware
Pam Bondi testifies
Reviews Texas age law
2 lunar landers launched
RU missile attack on UKR
Faces $650M+ DOJ lawsuit
No federal charges in death
Federal report on alcohol
FDA seeks to limit nicotine
Inflation ticked up to 2.9%
To lay off 5% of staff
Breaks Federer record
1st quarter deficit: $711B
Zelenskyy visits Poland
MS-13 member guilty
2025 BAFTA nominations
Hit with $100M verdict
New agency to collect tariffs
反馈